One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v128.22.234.234
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Dec 2, 2016 |
 Citations: 36 |
Affiliation: University of Rochester, Pharmacyclics (United States), AbbVie (United States), Rabin Medical Center, King's College Hospital NHS Foundation Trust, Medical University of Silesia, Jiangsu Province Hospital, University of California, San Diego, Ospedale Niguarda Ca' Granda, Hospital de Sant Pau, Vita-Salute San Raffaele University, Istituti di Ricovero e Cura a Carattere Scientifico, Royal Bournemouth Hospital, St James's University Hospital, North Shore Hospital, Medical University of Lodz, Universitair Ziekenhuis Brussel, Ghent University Hospital, Foothills Medical Centre, Stanford University, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis
Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
